Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Non-cash Items (2023 - 2025)

Monte Rosa Therapeutics (GLUE) has 3 years of Non-cash Items data on record, last reported at $15.8 million in Q3 2025.

  • For Q3 2025, Non-cash Items rose 282.39% year-over-year to $15.8 million; the TTM value through Sep 2025 reached $15.8 million, up 282.39%, while the annual FY2024 figure was $6.3 million, 33.78% up from the prior year.
  • Non-cash Items reached $15.8 million in Q3 2025 per GLUE's latest filing, up from $8.1 million in the prior quarter.
  • Across five years, Non-cash Items topped out at $15.8 million in Q3 2025 and bottomed at $1.8 million in Q2 2024.
  • Average Non-cash Items over 3 years is $6.2 million, with a median of $4.7 million recorded in 2023.
  • Peak YoY movement for Non-cash Items: tumbled 47.48% in 2024, then skyrocketed 339.87% in 2025.
  • A 3-year view of Non-cash Items shows it stood at $4.7 million in 2023, then soared by 140.86% to $11.4 million in 2024, then skyrocketed by 38.03% to $15.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-cash Items were $15.8 million in Q3 2025, $8.1 million in Q2 2025, and $7.5 million in Q1 2025.